Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter-Defibrillator Recipients Real-World Data from the Israeli National.

Slides:



Advertisements
Similar presentations
Prevalence and Predictors of Off-label Use of Cardiac Resynchronization Therapy: A Report from the ICD Registry TM Adam S. Fein * MD, Yongfei Wang ¥ MS,
Advertisements

The MADIT II Trial Multicenter Autonomic Defibrillator Implantation Trial II Presented at the American College of Cardiology 51st Annual Scientific Session.
Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010 ICD data.
Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
Natale MARRAZZO Francesco SOLIMENE Quando la CRT-P può bastare?
MADIT Randomized Trial to Reduce Inappropriate Therapy (MADIT-RIT) Arthur J. Moss, MD for the MADIT-RIT Executive Committee AHA Late Breaking Trials November.
Impact of Anticoagulant and Anti-platelet Therapy on ICD Implant-Related Bleeding and Thromboembolic Events in Patients Enrolled in the NCDR ® ICD Registry.
TWA Testing in the EP Lab u To guide performance of EP study u To guide interpretation of EP study u To provide independent information along with the.
Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.
Implantable Cardioverter Defibrillators to Prevent Sudden Cardiac Death: Background Frederick A. Masoudi, MD, MSPH Associate Professor of Medicine (Cardiology)
Outcome of Patients with Advanced Heart Failure who Receive Device- Based Therapy for Primary Prevention of Sudden Cardiac Death, G. Amit, N. Samniah,
Atrial Fibrillation and Sudden Death: Are they linked? Mariell Jessup MD Professor of Medicine University of Pennsylvania Philadelphia, Pennsylvania.
Gillian D Sanders Ph.D.Lurdes Y Inoue Ph.D. Associate Professor of MedicineAssociate Professor of Biostatistics Duke UniversityUniversity of Washington.
Jennifer Cohen, MD, Heather Costa, PhD, Robert Russo, MD, PhD, Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA The MagnaSafe Registry:
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Sudden death as co-morbidity in patients following vascular intervention Sudden death as co-morbidity in patients following vascular intervention Impact.
Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes Guy Amit, MD; Mahmoud Suleiman, MD; Mark Kazatsker,
Indications of ICD in 2010 Dr Mervat Aboulmaaty Professor of Cardiology Ain Shams University DAF 1 st EP course 2010.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Alon Barsheshet, MD1, Paul J. Wang, MD2, Arthur J. Moss, MD1, Scott D
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
Renal function and clinical outcomes of patients undergoing ICD and CRTD implantation- Data from the Israeli ICD Registry Alon Eisen, Mahmoud Souleiman,
Clinical Characteristics and Outcomes of Elderly Patients Treated With ICD and CRTD in Real World Setting: Data From the Israeli ICD Registry M. Suleiman,
Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.
Coverage with Evidence Development Implantable Cardioverter Defibrillators 1 Sean Tunis MD, MSc June 23, 2009.
Devices and the older patient with syncope Michael Gammage, Reader in Cardiovascular Medicine MHRA Committee for Safety of Devices.
M. JESSUP Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
IRIS Post-hoc Analysis Background IRIS compared the safety and efficacy of early ICD implantation with medical treatment alone in 898 patients at high.
Introduction Most patients undergoing left ventricular assist device (LVAD) implantation for destination therapy (DT) also have an implantable cardioverter.
INTRODUCTION: INTRODUCTION: implantable cardioverter-defibrillators (ICDs) have clearly demonstrated to terminate an elevated percentage of sustained ventricular.
EP show – June 2004 EP show The EP show: Risk stratification for sudden death Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent.
An ICD for every CRT patient ?
Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.
EP Show – Dec 2003 ICDs – Primary prevention The EP Show: Guidelines and reimbursement at the crossroads: Primary prevention with ICDs Eric Prystowsky.
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Life Threatening Ventricular Arrhythmias: Current Role of.
© 2008, American Heart Association. All rights reserved. AHA/ACC/HRS Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Increased Patient Device Concerns But Not General Anxiety in Patients with a Secondary Indication for the ICD Susanne S. Pedersen, Professor of Cardiac.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Inappropriate Implantable Cardioverter-Defibrillator.
CoRPS Center of Research on Psychology in Somatic diseases Poor health status in implantable cardioverter defibrillator patients: Shock, patient pre implantation.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA/ESC 2006 Guidelines for Management of Patients.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Interactions Between COPD and Outcomes After Percutaneous Coronary Intervention Tomas Konecny, Krishen Somers, Marek Orban, Yuki Koshino, Ryan J. Lennon,
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Indications for Implantable Cardioverter-Defibrillators.
Survival with Cardiac- Resynchronization Therapy in Mild Heart Failure.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical Effectiveness of CRT and ICD Therapy in.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Influence of Left Ventricular Ejection Fraction.
Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Limitations of Ejection Fraction for Prediction.
Author Disclosure Sex Differences in the Characteristics of Patients Receiving ICD Therapy for the Primary Prevention of Sudden Cardiac Death –Stacie L.
Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Hypertrophic Cardiomyopathy in Adulthood Associated.
Ventricular Arrhythmias:A General Cardiologist’s Assessment of Therapies in 2004 C.Richard Conti M.D. MACC.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Sudden Cardiac Arrest Morhaf Ibrahim, MD, FHRS Electrophysiology.
Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in CKD: A Meta-analysis of Patient-Level Data From 3 Randomized.
– р<0.05 between baseline
Update on the Watchman Device CRT 2010 Washington, DC
Simon A. Castro, MD; Daniele Muser, MD; Erica Zado, PA; Rajeev K
American College of Cardiology Presented by Dr. Stuart J. Connolly
Addressing Patients at High Risk for SCA
Jeff Macemon Waikato Cardiothoracic Unit
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
The most common cause of death in North America is cardiac death and the most common cause of cardiac death is sudden death from ventricular arrhythmias.
MASTER Trial Inclusion Criteria
Volume 13, Issue 1, Pages (January 2016)
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
Volume 16, Issue 6, Pages (June 2019)
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter-Defibrillator Recipients Real-World Data from the Israeli National ICD Registry Jorge E. Schliamser MD, Guy Amit MD, Moti Haim MD, Mahmoud Suleiman MD, Arie Militianu MD, Nissan Ben Dov MD, Aharon Glick MD, Vladimir Khalameizer MD, Natalie Gavrielov-Yusim MSc, Ilan Goldenberg MD, Michael Glikson, MD On Behalf of the Israeli Working Group on Pacing and Electrophysiology Jorge E. Schliamser MD, Guy Amit MD, Moti Haim MD, Mahmoud Suleiman MD, Arie Militianu MD, Nissan Ben Dov MD, Aharon Glick MD, Vladimir Khalameizer MD, Natalie Gavrielov-Yusim MSc, Ilan Goldenberg MD, Michael Glikson, MD On Behalf of the Israeli Working Group on Pacing and Electrophysiology

DisclosureDisclosure The study was supported by an unrestricted research grant from Boston Scientific to the Israeli Heart Society and the Israeli Association for Cardiovascular Trials The study was supported by an unrestricted research grant from Boston Scientific to the Israeli Heart Society and the Israeli Association for Cardiovascular Trials

BackgroundBackground Inducibility of ventricular arrhythmias with programmed electrical stimulation (PES) suggests an increased risk for sudden arrhythmic death Inducibility of ventricular arrhythmias with programmed electrical stimulation (PES) suggests an increased risk for sudden arrhythmic death MADIT I, MUSTT, MADIT II, DEFINITE Inducibility of ventricular arrhythmias with programmed electrical stimulation (PES) suggests an increased risk for sudden arrhythmic death Inducibility of ventricular arrhythmias with programmed electrical stimulation (PES) suggests an increased risk for sudden arrhythmic death MADIT I, MUSTT, MADIT II, DEFINITE

BackgroundBackground While earlier trials used PES for risk stratification of SCD, mainly in patients with coronary artery disease, recent data from RCTs, support a benefit of ICDs in patients with reduced LVEF without performing PES While earlier trials used PES for risk stratification of SCD, mainly in patients with coronary artery disease, recent data from RCTs, support a benefit of ICDs in patients with reduced LVEF without performing PES MADIT II, SCDHeFT While earlier trials used PES for risk stratification of SCD, mainly in patients with coronary artery disease, recent data from RCTs, support a benefit of ICDs in patients with reduced LVEF without performing PES While earlier trials used PES for risk stratification of SCD, mainly in patients with coronary artery disease, recent data from RCTs, support a benefit of ICDs in patients with reduced LVEF without performing PES MADIT II, SCDHeFT

PurposePurpose To evaluate the clinical characteristics and outcomes of patients enrolled in the Israeli National ICD Registry who underwent PES prior to device implantation To evaluate the clinical characteristics and outcomes of patients enrolled in the Israeli National ICD Registry who underwent PES prior to device implantation

Study Population Non inducible patients who did not receive a device, were not included in the registry Non inducible patients who did not receive a device, were not included in the registry 1188 registry patients (age 66.2±10.9, 89% male) who underwent device implantation were prospectively followed for a median period of 323 days 1188 registry patients (age 66.2±10.9, 89% male) who underwent device implantation were prospectively followed for a median period of 323 days Non inducible patients who did not receive a device, were not included in the registry Non inducible patients who did not receive a device, were not included in the registry 1188 registry patients (age 66.2±10.9, 89% male) who underwent device implantation were prospectively followed for a median period of 323 days 1188 registry patients (age 66.2±10.9, 89% male) who underwent device implantation were prospectively followed for a median period of 323 days

Programmed Electrical Stimulation No particular PES protocol was adopted No particular PES protocol was adopted Inducibility was reported by the implanting physician if monomorphic/polymorphic VT or VF was obtained at PES Inducibility was reported by the implanting physician if monomorphic/polymorphic VT or VF was obtained at PES No particular PES protocol was adopted No particular PES protocol was adopted Inducibility was reported by the implanting physician if monomorphic/polymorphic VT or VF was obtained at PES Inducibility was reported by the implanting physician if monomorphic/polymorphic VT or VF was obtained at PES

OutcomesOutcomes  First occurrence of appropriate ICD therapy for VT/VF and/or death

Arrhythmic Events Arrhythmic events were defined as ICD shocks or anti-tachycardia pacing for ventricular tachycardia or fibrillation (VT/VF) Arrhythmic events were defined as ICD shocks or anti-tachycardia pacing for ventricular tachycardia or fibrillation (VT/VF) Detection and therapy programming was up to the physician’s discretion Detection and therapy programming was up to the physician’s discretion Arrhythmic events were defined as ICD shocks or anti-tachycardia pacing for ventricular tachycardia or fibrillation (VT/VF) Arrhythmic events were defined as ICD shocks or anti-tachycardia pacing for ventricular tachycardia or fibrillation (VT/VF) Detection and therapy programming was up to the physician’s discretion Detection and therapy programming was up to the physician’s discretion

ResultsResults Of 2971 patients undergoing ICD implantation, 504 (17%) patients had PES prior to ICD implantation Of 2971 patients undergoing ICD implantation, 504 (17%) patients had PES prior to ICD implantation 413/504 (82%) patients belong to the primary prevention group 413/504 (82%) patients belong to the primary prevention group Among patients who underwent PES, 460 (91%) were inducible for VT/VF Among patients who underwent PES, 460 (91%) were inducible for VT/VF Of 2971 patients undergoing ICD implantation, 504 (17%) patients had PES prior to ICD implantation Of 2971 patients undergoing ICD implantation, 504 (17%) patients had PES prior to ICD implantation 413/504 (82%) patients belong to the primary prevention group 413/504 (82%) patients belong to the primary prevention group Among patients who underwent PES, 460 (91%) were inducible for VT/VF Among patients who underwent PES, 460 (91%) were inducible for VT/VF

Baseline Clinical Characteristics

Factors Independently Associated with the Performance of PES

Baseline Clinical Characteristics Thus, a lower baseline NYHA class, a higher baseline left ventricular ejection fraction (LVEF), lack of atrial fibrillation, and lack of treatment with diuretics were all independently associated with the performance of PES among registry patients, suggesting that patients selected for this procedure had less advanced heart failure Thus, a lower baseline NYHA class, a higher baseline left ventricular ejection fraction (LVEF), lack of atrial fibrillation, and lack of treatment with diuretics were all independently associated with the performance of PES among registry patients, suggesting that patients selected for this procedure had less advanced heart failure

Why Lower Risk Patients? Mainly, due to the need to proof pre- implantion inducibility in case of borderline clinical characteristics, as mandated by the major Israeli Health Care Provider (Clalit Health Services) Mainly, due to the need to proof pre- implantion inducibility in case of borderline clinical characteristics, as mandated by the major Israeli Health Care Provider (Clalit Health Services)

Clinical Outcomes by Performance of PES Clinical Outcomes by Performance of PES Among 1188 registry patients with available follow-up (positive PES 15%, no PES 76%) the rate of appropriate ICD therapy for VT/VF was similar between patients with a positive PES and those who underwent device implantation on the basis of LVEF alone Among 1188 registry patients with available follow-up (positive PES 15%, no PES 76%) the rate of appropriate ICD therapy for VT/VF was similar between patients with a positive PES and those who underwent device implantation on the basis of LVEF alone Regardless of non inducibility at PES, 9% of patients still received a device Regardless of non inducibility at PES, 9% of patients still received a device Among 1188 registry patients with available follow-up (positive PES 15%, no PES 76%) the rate of appropriate ICD therapy for VT/VF was similar between patients with a positive PES and those who underwent device implantation on the basis of LVEF alone Among 1188 registry patients with available follow-up (positive PES 15%, no PES 76%) the rate of appropriate ICD therapy for VT/VF was similar between patients with a positive PES and those who underwent device implantation on the basis of LVEF alone Regardless of non inducibility at PES, 9% of patients still received a device Regardless of non inducibility at PES, 9% of patients still received a device

Clinical Outcomes by Performance of PES Clinical Outcomes by Performance of PES The cumulative probability of VT/VF was 7% among patients with a positive PES prior to ICD implantation and 8% among patients in whom PES was not performed prior to device implantation, log-rank p-value=0.92 The cumulative probability of VT/VF was 7% among patients with a positive PES prior to ICD implantation and 8% among patients in whom PES was not performed prior to device implantation, log-rank p-value=0.92 Consistently, multivariate analysis showed similar VT/VF risk between the 2 groups (HR=0.95 [95%CI 0.71 – 1.28]; p=0.49) after adjustment for age, gender, type of prevention, NYHA, and LVEF Consistently, multivariate analysis showed similar VT/VF risk between the 2 groups (HR=0.95 [95%CI 0.71 – 1.28]; p=0.49) after adjustment for age, gender, type of prevention, NYHA, and LVEF The cumulative probability of VT/VF was 7% among patients with a positive PES prior to ICD implantation and 8% among patients in whom PES was not performed prior to device implantation, log-rank p-value=0.92 The cumulative probability of VT/VF was 7% among patients with a positive PES prior to ICD implantation and 8% among patients in whom PES was not performed prior to device implantation, log-rank p-value=0.92 Consistently, multivariate analysis showed similar VT/VF risk between the 2 groups (HR=0.95 [95%CI 0.71 – 1.28]; p=0.49) after adjustment for age, gender, type of prevention, NYHA, and LVEF Consistently, multivariate analysis showed similar VT/VF risk between the 2 groups (HR=0.95 [95%CI 0.71 – 1.28]; p=0.49) after adjustment for age, gender, type of prevention, NYHA, and LVEF

What About Primary Prevention? What About Primary Prevention?

ConclusionsConclusions

LimitationsLimitations Registry and not a randomized clinical trial Registry and not a randomized clinical trial Relatively short follow-up period Relatively short follow-up period PES has a low positive predictive value and a higher negative predictive value, and in fact, one of the study limitations is that the outcome of an indeterminate number of non-inducible patients in whom a device was not implanted and as a consequence not included in the registry, remains unknown, thereby, the net benefit of performing PES prior to implantation remains unascertained for this cohort and is beyond the scope of this analysis PES has a low positive predictive value and a higher negative predictive value, and in fact, one of the study limitations is that the outcome of an indeterminate number of non-inducible patients in whom a device was not implanted and as a consequence not included in the registry, remains unknown, thereby, the net benefit of performing PES prior to implantation remains unascertained for this cohort and is beyond the scope of this analysis Registry and not a randomized clinical trial Registry and not a randomized clinical trial Relatively short follow-up period Relatively short follow-up period PES has a low positive predictive value and a higher negative predictive value, and in fact, one of the study limitations is that the outcome of an indeterminate number of non-inducible patients in whom a device was not implanted and as a consequence not included in the registry, remains unknown, thereby, the net benefit of performing PES prior to implantation remains unascertained for this cohort and is beyond the scope of this analysis PES has a low positive predictive value and a higher negative predictive value, and in fact, one of the study limitations is that the outcome of an indeterminate number of non-inducible patients in whom a device was not implanted and as a consequence not included in the registry, remains unknown, thereby, the net benefit of performing PES prior to implantation remains unascertained for this cohort and is beyond the scope of this analysis

THANK YOU FOR YOUR ATTENTION